Regenxbio Stock Price, News & Analysis (NASDAQ:RGNX)

$26.45 -0.40 (-1.49 %)
(As of 02/20/2018 04:00 PM ET)
Previous Close$26.45
Today's Range$26.20 - $26.90
52-Week Range$16.30 - $36.45
Volume222,879 shs
Average Volume438,790 shs
Market Capitalization$823.79 million
P/E Ratio-9.76
Dividend YieldN/A
BetaN/A

About Regenxbio (NASDAQ:RGNX)

Regenxbio logoREGENXBIO Inc. is a clinical-stage biotechnology company. The Company's gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases. Its product candidate, RGX-314, is meant for the treatment of wet age-related macular degeneration (wet AMD). Its product candidate, RGX-501, is meant for the treatment of homozygous familial hypercholesterolemia (HoFH). It is also developing product candidates, such as RGX-111 and RGX-121, to address the neurological symptoms of two severe genetic lysosomal storage diseases, Mucopolysaccharidosis Type I (MPS I) and Mucopolysaccharidosis Type II (MPS II), respectively. Its product candidates utilize viral vectors from its gene delivery platform, NAV Technology Platform.

Receive RGNX News and Ratings via Email

Sign-up to receive the latest news and ratings for RGNX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:RGNX
CUSIPN/A
Phone+1-240-5528181

Debt

Debt-to-Equity RatioN/A
Current Ratio12.86%
Quick Ratio12.86%

Price-To-Earnings

Trailing P/E Ratio-9.76014760147601
Forward P/E Ratio-9.35
P/E GrowthN/A

Sales & Book Value

Annual Sales$4.59 million
Price / Sales179.50
Cash FlowN/A
Price / CashN/A
Book Value$6.11 per share
Price / Book4.33

Profitability

Trailing EPS($2.71)
Net Income$-62,960,000.00
Net Margins-764.06%
Return on Equity-39.33%
Return on Assets-36.98%

Miscellaneous

Employees107
Outstanding Shares31,150,000

Regenxbio (NASDAQ:RGNX) Frequently Asked Questions

What is Regenxbio's stock symbol?

Regenxbio trades on the NASDAQ under the ticker symbol "RGNX."

How were Regenxbio's earnings last quarter?

Regenxbio Inc (NASDAQ:RGNX) released its quarterly earnings data on Wednesday, November, 8th. The biotechnology company reported ($0.67) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.71) by $0.04. The biotechnology company earned $1.34 million during the quarter. Regenxbio had a negative return on equity of 39.33% and a negative net margin of 764.06%. View Regenxbio's Earnings History.

When will Regenxbio make its next earnings announcement?

Regenxbio is scheduled to release their next quarterly earnings announcement on Tuesday, March, 6th 2018. View Earnings Estimates for Regenxbio.

Where is Regenxbio's stock going? Where will Regenxbio's stock price be in 2018?

7 analysts have issued 12-month price objectives for Regenxbio's stock. Their forecasts range from $25.00 to $85.00. On average, they anticipate Regenxbio's share price to reach $41.00 in the next twelve months. View Analyst Ratings for Regenxbio.

What are Wall Street analysts saying about Regenxbio stock?

Here are some recent quotes from research analysts about Regenxbio stock:

  • 1. Chardan Capital analysts commented, "We have long highlighted the importance of vector science for the progress in GT; and, we see Commissioner Gottlieb’s comments as highly supportive of our views. We again highlight REGENXBIO (Buy) (a Chardan Top Pick for 2017, and our Gene Therapy Top Pick) as the best way to play the emergence of in vivo GT, due to the company’s: (1) rights to 100+ vectors, (2) partnerships with 10 companies, (3) 25 or so internal and external product candidates, over 10 of which are in clinical development, and (4) abundance of important 2017 catalysts, which to us represent upside options." (12/11/2017)
  • 2. According to Zacks Investment Research, "REGENXBIO Inc. is a biotechnology company. The Company focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Its products candidates include RGX-501, for the treatment of homozygous familial hypercholesterolemia which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; RGX-111, for the treatment of Mucopolysaccharidosis Type I which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system; RGX-121, for the treatment of Mucopolysaccharidosis Type II; RGX-314, for the treatment of wet age-related macular degeneration and RGX-321, for the treatment of X-linked retinitis pigmentosa. REGENXBIO Inc. is headquartered in Rockville, Maryland. " (11/17/2017)

Who are some of Regenxbio's key competitors?

Who are Regenxbio's key executives?

Regenxbio's management team includes the folowing people:

  • Donald J. Hayden Jr., Independent Chairman of the Board (Age 61)
  • Kenneth T. Mills, President, Chief Executive Officer, Executive Director (Age 42)
  • Vittal K. Vasista, Chief Financial Officer (Age 49)
  • Patrick J. Christmas, Senior Vice President, General Counsel (Age 46)
  • Curran M. Simpson, Senior Vice President - Technical Operations (Age 55)
  • Olivier Danos Ph.D., Chief Scientific Officer (Age 59)
  • Stephen Yoo M.D., Chief Medical Officer (Age 39)
  • Allan M. Fox, Director (Age 69)
  • Daniel J. Abdun-Nabi, Independent Director (Age 57)
  • Luke M. Beshar CPA, Independent Director (Age 59)

Who owns Regenxbio stock?

Regenxbio's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.33%), RTW Investments LP (5.01%), Redmile Group LLC (4.58%), Perceptive Advisors LLC (4.56%), Citadel Advisors LLC (3.17%) and Franklin Resources Inc. (2.80%). Company insiders that own Regenxbio stock include Curran Simpson, Donald J Hayden Jr, Fmr Llc, Kenneth T Mills, Stephen Yoo and Vittal Vasista. View Institutional Ownership Trends for Regenxbio.

Who sold Regenxbio stock? Who is selling Regenxbio stock?

Regenxbio's stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Redmile Group LLC, Ascend Capital LLC, Perceptive Advisors LLC, Franklin Resources Inc., Deutsche Bank AG, Goldman Sachs Group Inc. and Metropolitan Life Insurance Co. NY. Company insiders that have sold Regenxbio company stock in the last year include Curran Simpson, Donald J Hayden Jr, Kenneth T Mills, Stephen Yoo and Vittal Vasista. View Insider Buying and Selling for Regenxbio.

Who bought Regenxbio stock? Who is buying Regenxbio stock?

Regenxbio's stock was bought by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, Artal Group S.A., Two Sigma Investments LP, Royce & Associates LP, Hudson Bay Capital Management LP, Iguana Healthcare Management LLC, RTW Investments LP and Sphera Funds Management LTD.. View Insider Buying and Selling for Regenxbio.

How do I buy Regenxbio stock?

Shares of Regenxbio can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Regenxbio's stock price today?

One share of Regenxbio stock can currently be purchased for approximately $26.45.

How big of a company is Regenxbio?

Regenxbio has a market capitalization of $823.79 million and generates $4.59 million in revenue each year. The biotechnology company earns $-62,960,000.00 in net income (profit) each year or ($2.71) on an earnings per share basis. Regenxbio employs 107 workers across the globe.

How can I contact Regenxbio?

Regenxbio's mailing address is 9600 Blackwell Rd Ste 210, ROCKVILLE, MD 20850-3655, United States. The biotechnology company can be reached via phone at +1-240-5528181 or via email at [email protected]


MarketBeat Community Rating for Regenxbio (RGNX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  140 (Vote Outperform)
Underperform Votes:  118 (Vote Underperform)
Total Votes:  258
MarketBeat's community ratings are surveys of what our community members think about Regenxbio and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Regenxbio (NASDAQ:RGNX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.863.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $41.00$43.17$43.17$35.00
Price Target Upside: 53.27% upside22.63% upside48.34% upside58.01% upside

Regenxbio (NASDAQ:RGNX) Consensus Price Target History

Price Target History for Regenxbio (NASDAQ:RGNX)

Regenxbio (NASDAQ:RGNX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/12/2018MizuhoInitiated CoverageNeutral -> Neutral$28.00LowView Rating Details
1/5/2018Raymond James FinancialReiterated RatingBuyHighView Rating Details
12/11/2017Chardan CapitalReiterated RatingBuyHighView Rating Details
11/22/2017BarclaysInitiated CoverageOverweight$38.00N/AView Rating Details
11/9/2017Morgan StanleyReiterated RatingOverweight -> Overweight$34.00N/AView Rating Details
10/9/2017Bank of AmericaReiterated RatingBuy$33.00 -> $38.00N/AView Rating Details
8/16/2017Evercore ISIInitiated CoverageOutperform -> Outperform$25.00HighView Rating Details
11/13/2016Piper Jaffray CompaniesReiterated RatingBuy$25.00N/AView Rating Details
(Data available from 2/20/2016 forward)

Earnings

Regenxbio (NASDAQ:RGNX) Earnings History and Estimates Chart

Earnings by Quarter for Regenxbio (NASDAQ:RGNX)

Regenxbio (NASDAQ RGNX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/5/2018($0.79)N/AView Earnings Details
11/8/2017Q3 2017($0.71)($0.67)$1.34 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.81)($0.47)$6.56 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.76)($0.82)$0.46 millionViewListenView Earnings Details
3/7/2017Y 2016($0.75)($0.74)$1.70 millionViewListenView Earnings Details
11/9/2016Q3 2016($0.60)($0.69)$0.13 millionViewN/AView Earnings Details
8/9/2016Q2 2016($0.52)($0.55)$2.38 millionViewN/AView Earnings Details
5/5/2016($0.40)($0.41)$0.39 millionViewN/AView Earnings Details
3/3/2016Q415($0.34)($0.20)$1.23 million$4.40 millionViewN/AView Earnings Details
11/5/2015Q315($0.35)($1.52)$1.10 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Regenxbio (NASDAQ:RGNX) Earnings Estimates

Current Year EPS Consensus Estimate: $-2.83 EPS
Next Year EPS Consensus Estimate: $-2.58 EPS

Dividends

Dividend History for Regenxbio (NASDAQ:RGNX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Regenxbio (NASDAQ RGNX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 17.00%
Institutional Ownership Percentage: 66.85%
Insider Trades by Quarter for Regenxbio (NASDAQ:RGNX)
Institutional Ownership by Quarter for Regenxbio (NASDAQ:RGNX)

Regenxbio (NASDAQ RGNX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/22/2018Kenneth T MillsInsiderSell10,000$27.33$273,300.00248,530View SEC Filing  
1/16/2018Vittal VasistaCFOSell5,000$30.16$150,800.00View SEC Filing  
12/22/2017Curran SimpsonSVPSell30,000$33.03$990,900.0069,500View SEC Filing  
12/20/2017Kenneth T MillsInsiderSell10,000$31.75$317,500.00108,530View SEC Filing  
12/19/2017Vittal VasistaCFOSell5,000$30.00$150,000.0087,277View SEC Filing  
12/7/2017Curran SimpsonSVPSell21,890$30.04$657,575.6041,390View SEC Filing  
12/4/2017Curran SimpsonSVPSell110$30.00$3,300.0039,610View SEC Filing  
11/27/2017Curran SimpsonSVPSell2,000$29.31$58,620.0041,500View SEC Filing  
11/20/2017Kenneth T MillsInsiderSell10,000$27.71$277,100.00View SEC Filing  
10/20/2017Kenneth T MillsInsiderSell10,000$32.62$326,200.0098,730View SEC Filing  
10/16/2017Vittal VasistaCFOSell5,000$33.25$166,250.0092,283View SEC Filing  
10/11/2017Donald J Hayden JrDirectorSell20,000$34.95$699,000.00View SEC Filing  
9/27/2017Donald J Hayden JrDirectorSell20,000$32.45$649,000.0020,000View SEC Filing  
9/20/2017Kenneth T MillsInsiderSell10,000$29.33$293,300.00108,630View SEC Filing  
9/18/2017Donald J Hayden JrDirectorSell40,000$28.70$1,148,000.0020,000View SEC Filing  
9/15/2017Vittal VasistaCFOSell5,000$27.39$136,950.0099,594View SEC Filing  
9/8/2017Stephen YooInsiderSell27,342$25.00$683,550.0027,342View SEC Filing  
9/6/2017Stephen YooInsiderSell32,658$25.00$816,450.0031,803View SEC Filing  
9/5/2017Donald J Hayden JrDirectorSell20,000$24.95$499,000.0020,000View SEC Filing  
9/5/2017Kenneth T MillsInsiderSell10,500$25.00$262,500.00118,530View SEC Filing  
8/21/2017Kenneth T MillsInsiderSell6,500$20.05$130,325.00105,500View SEC Filing  
8/15/2017Vittal VasistaCFOSell3,040$21.09$64,113.60103,118View SEC Filing  
7/20/2017Kenneth T MillsInsiderSell6,500$18.66$121,290.00112,000View SEC Filing  
7/17/2017Vittal VasistaCFOSell3,100$19.81$61,411.00108,423View SEC Filing  
6/20/2017Kenneth T MillsInsiderSell6,500$19.68$127,920.00119,396View SEC Filing  
6/15/2017Vittal VasistaCFOSell3,100$18.75$58,125.00107,512View SEC Filing  
4/24/2017Donald J Hayden JrDirectorSell10,000$20.98$209,800.0028,599View SEC Filing  
4/24/2017Kenneth T MillsInsiderSell15,440$20.98$323,931.20126,395View SEC Filing  
4/24/2017Vittal VasistaCFOSell3,100$21.00$65,100.00114,039View SEC Filing  
5/17/2016Fmr LlcInsiderSell18,300$12.41$227,103.00View SEC Filing  
5/16/2016Fmr LlcInsiderSell16,030$11.65$186,749.50View SEC Filing  
5/12/2016Fmr LlcInsiderSell6,711$10.85$72,814.35View SEC Filing  
5/11/2016Fmr LlcInsiderSell25,132$10.36$260,367.52View SEC Filing  
5/9/2016Fmr LlcInsiderSell10,570$9.94$105,065.80View SEC Filing  
5/4/2016Fmr LlcInsiderSell1,896$10.51$19,926.96View SEC Filing  
5/3/2016Fmr LlcInsiderSell6,046$10.76$65,054.96View SEC Filing  
4/29/2016Fmr LlcInsiderSell4,723$10.80$51,008.40View SEC Filing  
4/28/2016Fmr LlcInsiderSell33,196$11.23$372,791.08View SEC Filing  
4/26/2016Fmr LlcInsiderSell9,188$11.19$102,813.72View SEC Filing  
4/22/2016Fmr LlcInsiderSell20,558$11.30$232,305.40View SEC Filing  
4/20/2016Fmr LlcInsiderSell13,189$11.66$153,783.74View SEC Filing  
4/18/2016Fmr LlcInsiderSell18,900$11.75$222,075.00View SEC Filing  
4/14/2016Fmr LlcInsiderSell27,036$11.46$309,832.56View SEC Filing  
9/22/2015James E FlynnInsiderBuy175,000$22.00$3,850,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Regenxbio (NASDAQ RGNX) News Headlines

Source:
DateHeadline
-$0.71 EPS Expected for Regenxbio Inc (RGNX) This Quarter-$0.71 EPS Expected for Regenxbio Inc (RGNX) This Quarter
www.americanbankingnews.com - February 20 at 11:16 PM
Mizuho Initiates Coverage on Regenxbio (RGNX)Mizuho Initiates Coverage on Regenxbio (RGNX)
www.americanbankingnews.com - February 12 at 8:28 PM
Regenxbio Inc (NASDAQ:RGNX): Financial Strength AnalysisRegenxbio Inc (NASDAQ:RGNX): Financial Strength Analysis
finance.yahoo.com - February 12 at 4:20 PM
BidaskClub Upgrades Regenxbio (RGNX) to BuyBidaskClub Upgrades Regenxbio (RGNX) to Buy
www.americanbankingnews.com - February 10 at 9:24 AM
Regenxbio (RGNX) Reports Completion of Dosing of Third Cohort in Phase I Clinical Trial of RGX-314 Gene Therapy for Wet AMDRegenxbio (RGNX) Reports Completion of Dosing of Third Cohort in Phase I Clinical Trial of RGX-314 Gene Therapy for Wet AMD
www.streetinsider.com - February 9 at 9:23 AM
REGENXBIO Announces Completion of Dosing of Third Cohort in Phase I Clinical Trial of RGX-314 Gene Therapy for Wet AMDREGENXBIO Announces Completion of Dosing of Third Cohort in Phase I Clinical Trial of RGX-314 Gene Therapy for Wet AMD
finance.yahoo.com - February 8 at 4:14 PM
REGENXBIO to Participate in Upcoming Investor ConferencesREGENXBIO to Participate in Upcoming Investor Conferences
finance.yahoo.com - February 8 at 8:46 AM
Regenxbio Inc (RGNX) Receives Consensus Rating of "Buy" from AnalystsRegenxbio Inc (RGNX) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - February 7 at 3:24 AM
BidaskClub Lowers Regenxbio (RGNX) to HoldBidaskClub Lowers Regenxbio (RGNX) to Hold
www.americanbankingnews.com - February 2 at 6:52 AM
Kenneth T. Mills Sells 10,000 Shares of Regenxbio Inc (RGNX) StockKenneth T. Mills Sells 10,000 Shares of Regenxbio Inc (RGNX) Stock
www.americanbankingnews.com - January 24 at 6:50 PM
REGENXBIO Enhances Gene Therapy Manufacturing Capabilities by Entering into Strategic Partnership with FUJIFILM Diosynth BiotechnologiesREGENXBIO Enhances Gene Therapy Manufacturing Capabilities by Entering into Strategic Partnership with FUJIFILM Diosynth Biotechnologies
finance.yahoo.com - January 24 at 9:50 AM
Vittal Vasista Sells 5,000 Shares of Regenxbio Inc (RGNX) StockVittal Vasista Sells 5,000 Shares of Regenxbio Inc (RGNX) Stock
www.americanbankingnews.com - January 18 at 7:58 PM
-$0.71 Earnings Per Share Expected for Regenxbio Inc (RGNX) This Quarter-$0.71 Earnings Per Share Expected for Regenxbio Inc (RGNX) This Quarter
www.americanbankingnews.com - January 18 at 1:42 AM
Regenxbio Inc (RGNX) Given Average Recommendation of "Buy" by BrokeragesRegenxbio Inc (RGNX) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - January 13 at 4:01 AM
Stocks With Rising Relative Price Strength: RegenxbioStocks With Rising Relative Price Strength: Regenxbio
finance.yahoo.com - January 11 at 12:00 PM
[$$] Gene-Therapy Update: Mixed Results Dont Dim Hopes[$$] Gene-Therapy Update: Mixed Results Don't Dim Hopes
finance.yahoo.com - January 8 at 3:44 PM
REGENXBIO and AveXis Announce Expansion of Relationship through Amended License Agreement for the Development and Commercialization of Treatments for Spinal Muscular AtrophyREGENXBIO and AveXis Announce Expansion of Relationship through Amended License Agreement for the Development and Commercialization of Treatments for Spinal Muscular Atrophy
finance.yahoo.com - January 8 at 8:32 AM
Here's Why Regenxbio Dropped as Much as 17.6% TodayHere's Why Regenxbio Dropped as Much as 17.6% Today
finance.yahoo.com - January 5 at 3:40 PM
Raymond James Financial Reiterates Buy Rating for Regenxbio (RGNX)Raymond James Financial Reiterates Buy Rating for Regenxbio (RGNX)
www.americanbankingnews.com - January 5 at 1:34 PM
Analyzing Regenxbio (RGNX) and Its RivalsAnalyzing Regenxbio (RGNX) and Its Rivals
www.americanbankingnews.com - January 5 at 7:28 AM
Regenxbio Inc (RGNX) Expected to Post Earnings of -$0.71 Per ShareRegenxbio Inc (RGNX) Expected to Post Earnings of -$0.71 Per Share
www.americanbankingnews.com - January 1 at 7:28 AM
ETFs with exposure to REGENXBIO, Inc. : December 28, 2017ETFs with exposure to REGENXBIO, Inc. : December 28, 2017
finance.yahoo.com - December 28 at 5:00 PM
Regenxbio Inc (RGNX) SVP Curran Simpson Sells 30,000 SharesRegenxbio Inc (RGNX) SVP Curran Simpson Sells 30,000 Shares
www.americanbankingnews.com - December 28 at 3:42 PM
Regenxbio Sees Unusually High Options Volume (RGNX)Regenxbio Sees Unusually High Options Volume (RGNX)
www.americanbankingnews.com - December 28 at 2:38 AM
REGENXBIO, Inc. :RGNX-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017REGENXBIO, Inc. :RGNX-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017
finance.yahoo.com - December 27 at 11:18 AM
Reviewing Regenxbio (RGNX) and Verastem (VSTM)Reviewing Regenxbio (RGNX) and Verastem (VSTM)
www.americanbankingnews.com - December 25 at 1:18 PM
Regenxbio (RGNX) Upgraded by BidaskClub to Strong-BuyRegenxbio (RGNX) Upgraded by BidaskClub to Strong-Buy
www.americanbankingnews.com - December 22 at 6:13 PM
Regenxbio Inc (RGNX) Insider Kenneth T. Mills Sells 10,000 SharesRegenxbio Inc (RGNX) Insider Kenneth T. Mills Sells 10,000 Shares
www.americanbankingnews.com - December 21 at 5:24 PM
Regenxbio Shows Rising Price Performance With Jump To 93 RS RatingRegenxbio Shows Rising Price Performance With Jump To 93 RS Rating
finance.yahoo.com - December 21 at 11:28 AM
Regenxbio Inc (RGNX) CFO Vittal Vasista Sells 5,000 SharesRegenxbio Inc (RGNX) CFO Vittal Vasista Sells 5,000 Shares
www.americanbankingnews.com - December 20 at 6:04 PM
REGENXBIO, Inc. is trading above its 50 day moving average : RGNX-US : December 20, 2017REGENXBIO, Inc. is trading above its 50 day moving average : RGNX-US : December 20, 2017
finance.yahoo.com - December 20 at 11:27 AM
BRIEF-Regenxbio Announces IND Active For Phase I/II Trial Of RGX-121 To Treat Mucopolysaccharidosis Type IIBRIEF-Regenxbio Announces IND Active For Phase I/II Trial Of RGX-121 To Treat Mucopolysaccharidosis Type II
www.reuters.com - December 19 at 3:38 PM
Regenxbio Inc (RGNX) Receives Average Recommendation of "Buy" from AnalystsRegenxbio Inc (RGNX) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - December 19 at 3:36 AM
 Analysts Expect Regenxbio Inc (RGNX) to Announce -$0.71 Earnings Per Share Analysts Expect Regenxbio Inc (RGNX) to Announce -$0.71 Earnings Per Share
www.americanbankingnews.com - December 15 at 11:06 AM
Reviewing Regenxbio (RGNX) and Its CompetitorsReviewing Regenxbio (RGNX) and Its Competitors
www.americanbankingnews.com - December 15 at 9:14 AM
Regenxbio (RGNX) Stock Rating Reaffirmed by Chardan CapitalRegenxbio (RGNX) Stock Rating Reaffirmed by Chardan Capital
www.americanbankingnews.com - December 11 at 7:16 PM
Regenxbio Inc (RGNX) SVP Sells $657,575.60 in StockRegenxbio Inc (RGNX) SVP Sells $657,575.60 in Stock
www.americanbankingnews.com - December 11 at 5:38 PM
Regenxbio (RGNX) Upgraded to Buy by BidaskClubRegenxbio (RGNX) Upgraded to Buy by BidaskClub
www.americanbankingnews.com - December 9 at 12:51 PM
REGENXBIO, Inc. breached its 50 day moving average in a Bullish Manner : RGNX-US : December 8, 2017REGENXBIO, Inc. breached its 50 day moving average in a Bullish Manner : RGNX-US : December 8, 2017
finance.yahoo.com - December 8 at 11:39 AM
Regenxbio Joins Rank Of Stocks With RS Ratings Over 90Regenxbio Joins Rank Of Stocks With RS Ratings Over 90
finance.yahoo.com - December 7 at 11:53 AM
REGENXBIO (RGNX) Lowered to "D+" at TheStreetREGENXBIO (RGNX) Lowered to "D+" at TheStreet
www.americanbankingnews.com - November 30 at 9:43 AM
Curran Simpson Sells 2,000 Shares of REGENXBIO Inc. (RGNX) StockCurran Simpson Sells 2,000 Shares of REGENXBIO Inc. (RGNX) Stock
www.americanbankingnews.com - November 29 at 8:46 PM
REGENXBIO Inc. (RGNX) Downgraded by ValuEngineREGENXBIO Inc. (RGNX) Downgraded by ValuEngine
www.americanbankingnews.com - November 26 at 9:00 AM
REGENXBIO Inc. (RGNX) Receives Consensus Recommendation of "Buy" from AnalystsREGENXBIO Inc. (RGNX) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - November 24 at 3:56 AM
REGENXBIO Inc. (RGNX) Coverage Initiated by Analysts at Barclays PLCREGENXBIO Inc. (RGNX) Coverage Initiated by Analysts at Barclays PLC
www.americanbankingnews.com - November 22 at 12:56 PM
Kenneth T. Mills Sells 10,000 Shares of REGENXBIO Inc. (RGNX) StockKenneth T. Mills Sells 10,000 Shares of REGENXBIO Inc. (RGNX) Stock
www.americanbankingnews.com - November 21 at 8:44 PM
REGENXBIO Inc. (RGNX) Downgraded to Hold at Zacks Investment ResearchREGENXBIO Inc. (RGNX) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - November 17 at 6:24 AM
Five Prime Therapeutics (FPRX) versus REGENXBIO (RGNX) Head to Head ContrastFive Prime Therapeutics (FPRX) versus REGENXBIO (RGNX) Head to Head Contrast
www.americanbankingnews.com - November 16 at 11:16 PM
Edited Transcript of RGNX earnings conference call or presentation 8-Nov-17 9:30pm GMTEdited Transcript of RGNX earnings conference call or presentation 8-Nov-17 9:30pm GMT
finance.yahoo.com - November 12 at 12:21 PM
REGENXBIO (RGNX) & Paratek Pharmaceuticals (PRTK) Critical AnalysisREGENXBIO (RGNX) & Paratek Pharmaceuticals (PRTK) Critical Analysis
www.americanbankingnews.com - November 12 at 3:10 AM

SEC Filings

Regenxbio (NASDAQ:RGNX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Regenxbio (NASDAQ:RGNX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Regenxbio (NASDAQ RGNX) Stock Chart for Tuesday, February, 20, 2018

Loading chart…

This page was last updated on 2/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.